Top Industry Leaders in the Hemiplegic Migraine Market
Latest Hemiplegic Migraine Companies Update:
Alder BioPharmaceuticals initiates Phase 3 study of ALDER-1123 as a preventive treatment for hemiplegic migraine. This drug candidate acts on the calcitonin gene-related peptide (CGRP) receptor, targeting a potential mechanism underlying hemiplegic migraine attacks. (Jan 9, 2024)
Lundbeck announces positive results from a Phase 2b study of its CGRP antibody, LY3295157, in preventing episodic migraine, including hemiplegic migraine. This study provides further evidence for CGRP-targeting therapies in hemiplegic migraine management. (Nov 15, 2023)
Biogen and Samsung Biologics enter into a strategic partnership to develop and manufacture novel antibody-based therapies for neurological disorders, potentially including hemiplegic migraine. This collaboration combines Biogen's expertise in drug discovery with Samsung's manufacturing capabilities.
List of Hemiplegic Migraine Key companies in the market
- Abbott Laboratories
- Allergan Plc.
- AstraZeneca
- Eisai Co., Ltd.
- Endo International Plc.
- GlaxoSmithKline Plc.
- Impax Laboratories
- Eli Lily and Company
- Johnson & Johnson
- Merck & Co.